Furthermore, SGLT2 inhibitor use was associated with a lower risk of sepsis (RR 0.32, 95% CI 0.23–0.44, P < 0.00001) and no increased risk of diabetic ketoacidosis (RR 0.66, 95% CI 0.20–2.16, P = 0.49). The gene discussed is SLC5A2; the disease is Sepsis.